Associate Professor Georgina Long

Associate Professor of Melanoma Biology and Translational Research
Medicine, Central Clinical School

Telephone +61 2 9911 7336
Curriculum vitae Curriculum vitae

Map

Biographical details

Associate Professor Georgina Long BSc PhD MBBS FRACP is a clinical researcher and Medical Oncologist at Melanoma Institute Australia, University of Sydney. She is the author of over 80 peer-reviewed publications in clinical and translational research in melanoma since 2011 and has presented her work at international conferences and meetings on more than 100 occasions.

Georgina is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular focus on clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance. In recognition of her ground breaking research, Associate Professor Long has received a number of awards at the CINSW Premier’s Awards for Outstanding Cancer Research: in 2014, she was awarded the Wildfire Award for the most highly-cited, original, peer-reviewed article published in 2011, and in 2013 was the Outstanding Cancer Research Fellow. Georgina is also the recipient of a Cancer Institute NSW Fellowship, was awarded a University Medal in Chemistry prior to commencing a PhD in Chemistry and medical studies (MBBS) at the University of Sydney, and was awarded a Fulbright Postdoctoral Fellowship at Scripps Research Institute, USA. Georgina became a Fellow of the Australasian College of Physicians after completing Medical Oncology training in Sydney, Australia.

International links

United States

(M.D Anderson, Harvard, Vanderbilt-Ingram Cancer Center, Washington University, University of California, Los Angeles, University of Pennsylvania, John Wayne Cancer Centre) Collaborations across multiple USA institutions including both clinical and translational studies of melanoma epidemiology, prognosis, resistance/response to systemic therapies

Selected grants

2014

  • 2014 Premiers Award for Outstanding Research Fellow; Long G; Cancer Institute New South Wales/Premier's Award.
  • MAPK reactivation drives melanoma resistance to MAPK inhibition; Rizos H, Kefford R, Long G; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Melanoma resistance to combination BRAF and MEK inhibition is driven by reprogramming of MAPK signaling; Rizos H, Kefford R, Long G; National Health and Medical Research Council (NHMRC)/Project Grants.

2013

  • 2013 Premiers Award for Outstanding Research Fellow; Long G; Cancer Institute New South Wales/Premier's Award.

2011

  • Determining mechanisms of resistance and heterogeneity of response to novel targeted drugs in metastatic melanoma to improve survival and prevent metastatic disease.; Long G; Cancer Institute New South Wales/Career Development Fellowship.
  • Manipulating the B-RAF/MEK pathway in the genesis and treatment of melanoma; Rizos H, Kefford R, Long G, Zhang X; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Shi, H., Hong, A., Kong, X., Koya, R., Song, C., Moriceau, G., Hugo, W., Yu, C., Ng, C., Chodon, T., Scolyer, R., Kefford, R., Long, G., et al (2014). A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. Cancer Discovery, 4(1), 69-79. [More Information]
  • Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R., Moriceau, G., Chodon, T., Guo, R., Johnson, D., Dahlman, K., Kefford, R., Long, G., et al (2014). Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discovery, 4(1), 80-93. [More Information]
  • Bowyer, S., Rao, A., Lyle, M., Sandhu, S., Long, G., McArthur, G., Raleigh, J., Hicks, R., Millward, M. (2014). Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Research, 24(5), 504-508. [More Information]
  • Rizos, H., Menzies, A., Pupo, G., Carlino, M., Fung, C., Hyman, J., Haydu, L., Mijatov, B., Becker, T., Boyd, S., Howle, J., Saw, R., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2014). BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Research, 20(7), 1965-1977. [More Information]
  • Kakavand, H., Crainic, O., Lum, T., O'Toole, S., Kefford, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2014). Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 46(3), 193-198. [More Information]
  • Menzies, A., Long, G. (2014). Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clinical Cancer Research, 20(8), 2035-2043. [More Information]
  • Carlino, M., Todd, J., Gowrishankar, K., Mijatov, B., Pupo, G., Fung, C., Snoyman, S., Hersey, P., Long, G., Kefford, R., Rizos, H. (2014). Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology, 8(3), 544-554. [More Information]
  • Falchook, G., Long, G., Kurzrock, R., Kim, K., Arkenau, H., Brown, M., Hamid, O., Infante, J., Millward, M., Pavlick, A., Kefford, R., et al (2014). Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF-inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research, 20(17), 4449-4458. [More Information]
  • Wilmott, J., Haydu, L., Menzies, A., Lum, T., Hyman, J., Thompson, J., Hersey, P., Kefford, R., Scolyer, R., Long, G. (2014). Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. The Journal of Immunology, 192(5), 2505-2513. [More Information]
  • Lee, C., Menzies, A., Haydu, L., Azer, M., Clements, A., Kefford, R., Long, G. (2014). Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Melanoma Research: a journal for basic, translational and clinical research in melanoma, 24(5), 468-474. [More Information]
  • Zimmer, L., Haydu, L., Menzies, A., Scolyer, R., Kefford, R., Thompson, J., Schadendorf, D., Long, G. (2014). Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. Journal of Clinical Oncology, 32(8), 816-823. [More Information]
  • Menzies, A., Haydu, L., Carlino, M., Azer, M., Carr, P., Kefford, R., Long, G. (2014). Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PLoS One, 9(1), 1-9. [More Information]
  • Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
  • Ackerman, A., Klein, O., McDermott, D., Wang, W., Ibrahim, N., Lawrence, D., Gunturi, A., Flaherty, K., Hodi, F., Kefford, R., Menzies, A., Long, G., et al (2014). Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer, 120(11), 1695-1701. [More Information]
  • Azer, M., Menzies, A., Haydu, L., Kefford, R., Long, G. (2014). Patterns of Response and Progression in Patients With BRAF-Mutant Melanoma Metastatic to the Brain Who Were Treated With Dabrafenib. Cancer, 120(4), 530-536. [More Information]
  • Parmenter, T., Kleinschmidt, M., Kinross, K., Bond, S., Li, J., Kaadige, M., Rao, A., Sheppard, K., Hugo, W., Pupo, G., Long, G., Scolyer, R., Rizos, H., et al (2014). Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discovery, 4(4), 423-433. [More Information]
  • Flaherty, K., Hennig, M., Ascierto, P., Dummer, R., Eggermont, A., Hauschild, A., Kefford, R., Kirkwood, J., Long, G., Lorigan, P., et al (2014). Surrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trials. The Lancet Oncology, 15(3), 297-304. [More Information]
  • Chien, A., Haydu, L., Biechele, T., Kulikauskas, R., Rizos, H., Kefford, R., Scolyer, R., Moon, R., Long, G. (2014). Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/Beta-Catenin Signaling. PLoS One, 9(4), 1-11. [More Information]
  • Lyle, M., Long, G. (2014). The role of systemic therapies in the management of melanoma brain metastases. Current Opinion in Oncology, 26(2), 22-229. [More Information]
  • Brown, M., Long, G. (2014). The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation. Asia-Pacific Journal of Clinical Oncology, 10(S3), 1-15. [More Information]
  • Carlino, M., Saunders, C., Haydu, L., Menzies, A., Curtis, C., Lebowitz, P., Kefford, R., Long, G. (2013). 18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. European Journal of Cancer, 49(2), 395-402. [More Information]
  • Hu, W., Jin, L., Jiang, C., Long, G., Scolyer, R., Wu, Q., Zhang, X., Mei, Y., Wu, M. (2013). AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Cell Death and Disease, 4(e914), 1-11. [More Information]
  • Carlino, M., Gowrishankar, K., Saunders, C., Pupo, G., Snoyman, S., Zhang, X., Saw, R., Becker, T., Kefford, R., Long, G., Rizos, H. (2013). Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition Following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 12(7), 1332-1342. [More Information]
  • Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013). BRAF inhibitor activity in V600R metastatic melanoma. European Journal of Cancer, 49(5), 1073-1079. [More Information]
  • Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013). BRAF inhibitor activity in V600R metastatic melanoma – Response. European Journal of Cancer, 49(7), 1797-1798. [More Information]
  • Wilmott, J., Menzies, A., Haydu, L., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Diemling, A., Scolyer, R., Long, G. (2013). BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. British Journal of Cancer, 108(4), 924-931. [More Information]
  • Anforth, R., Fernandez Penas, P., Long, G. (2013). Cutaneous toxicities of RAF inhibitors. The Lancet Oncology, 14(1), e11-e18. [More Information]
  • Lyle, M., Long, G. (2013). Diagnosis and Treatment of KIT-Mutant Metastatic Melanoma. Journal of Clinical Oncology, 31(26), 3176-3181. [More Information]
  • Long, G., Wilmott, J., Haydu, L., Tembe, V., Sharma, R., Rizos, H., Thompson, J., Howle, J., Scolyer, R., Kefford, R. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment and on progression. Pigment Cell and Melanoma Research, 26(4), 499-508. [More Information]
  • Klein, O., Ribas, A., Chmielowski, B., Walker, G., Clements, A., Long, G., Kefford, R. (2013). Facial Palsy As a Side Effect of Vemurafenib Treatment in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 31(12), e215-e217. [More Information]
  • Long, G., Wilmott, J., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Deimling, A., Scolyer, R. (2013). Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. The American Journal of Surgical Pathology, 37(1), 61-65. [More Information]
  • Long, G., Margolin, K. (2013). Multidisciplinary Approach to Brain Metastasis from Melanoma: The Emerging Role of Systemic Therapies. American Society of Clinical Oncology Educational Book, 2013, 393-398. [More Information]
  • Menzies, A., Long, G. (2013). New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Therapeutic Advances in Medical Oncology, 5(5), 278-285. [More Information]
  • Menzies, A., Kefford, R., Long, G. (2013). Paradoxical oncogenesis: are all BRAF inhibitors equal? Pigment Cell and Melanoma Research, 26(5), 611-615. [More Information]
  • Trunzer, K., Pavlick, A., Schuchter, L., Gonzalez, R., McArthur, G., Hutson, T., Moschos, S., Flaherty, K., Kim, K., Weber, J., Hersey, P., Long, G., et al (2013). Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 31(14), 1767-1774. [More Information]
  • Kim, K., Kefford, R., Pavlick, A., Infante, J., Ribas, A., Sosman, J., Fecher, L., Millward, M., McArthur, G., Hwu, P., Long, G., et al (2013). Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology, 31(4), 482-489. [More Information]
  • Ascierto, P., Minor, D., Ribas, A., Lebbe, C., O'Hagan, A., Arya, N., Guckert, M., Schadendorf, D., Kefford, R., Grob, J., Long, G., et al (2013). Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 31(26), 3205-3211. [More Information]
  • Menzies, A., Long, G. (2013). Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. European Journal of Cancer, 49(15), 3229-3241. [More Information]
  • Anforth, R., Blumetti, T., Clements, A., Kefford, R., Long, G., Fernandez Penas, P. (2013). Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. British Journal of Dermatology, 169(6), 1310-1313. [More Information]
  • Nathanson, K., Martin, A., Wubbenhorst, B., Greshock, J., Letrero, R., D'Andrea, K., O'Day, S., Infante, J., Falchook, G., Arkenau, H., Kefford, R., Long, G., et al (2013). Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research, 19(17), 4868-4878. [More Information]
  • Zimmer, L., Hillen, U., Livingstone, E., Lacouture, M., Busam, K., Carvajal, R., Egberts, F., Hauschild, A., Kashani-Sabet, M., Goldinger, S., Long, G., et al (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology, 30(19), 2375-2383. [More Information]
  • Murali, R., Haydu, L., Long, G., Quinn, M., Saw, R., Shannon, K., Spillane, A., Stretch, J., Kefford, R., Thompson, J., Scolyer, R. (2012). Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. Annals of Surgical Oncology, 19(6), 1782-1789. [More Information]
  • Flaherty, K., Infante, J., Daud, A., Gonzalez, R., Kefford, R., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., Long, G., et al (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England Journal of Medicine, 367(18), 1694-1703. [More Information]
  • Wilmott, J., Scolyer, R., Long, G., Hersey, P. (2012). Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. OncoImmunology, 1(6), 997-999. [More Information]
  • Anforth, R., Blumetti, T., Kefford, R., Sharma, R., Scolyer, R., Kossard, S., Long, G., Fernandez Penas, P. (2012). Cutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of Mutant BRAF in patients with Metastatic Melanoma. British Journal of Dermatology, 167(5), 1153-1160. [More Information]
  • Menzies, A., Long, G., Murali, R. (2012). Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design, Development and Therapy, 6, 391-405. [More Information]
  • Falchook, G., Long, G., Kurzrock, R., Kim, K., Arkenau, T., Brown, M., Hamid, O., Infante, J., Millward, M., Pavlick, A., Kefford, R., et al (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. The Lancet, 379(9829), 1893-1901. [More Information]
  • Long, G., Trefzer, U., Davies, M., Kefford, R., Ascierto, P., Chapman, P., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., et al (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. The Lancet Oncology, 13(11), 1087-1095. [More Information]
  • Menzies, A., Haydu, L., Visintin, L., Carlino, M., Howle, J., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2012). Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clinical Cancer Research, 18(12), 3242-3249. [More Information]
  • Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012). Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 11(12), 2704-2708. [More Information]
  • Shi, H., Moriceau, G., Kong, X., Lee, M., Lee, H., Koya, R., Ng, C., Chodon, T., Scolyer, R., Dahlman, K., Kefford, R., Long, G., et al (2012). Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications, 3(20122), 1-8. [More Information]
  • Murali, R., Brown, P., Kefford, R., Scolyer, R., Thompson, J., Atkins, M., Long, G. (2012). Number of Primary Melanomas Is an Independent Predictor of Survival in Patients With Metastatic Melanoma. Cancer, 118(18), 4519-4529. [More Information]
  • Shi, H., Moriceau, G., Kong, X., Koya, R., Nazarian, R., Pupo, G., Bacchiocchi, A., Dahlman, K., Chmielowski, B., Sosman, J., Kefford, R., Long, G., et al (2012). Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discovery, 2(5), 414-424. [More Information]
  • Wilmott, J., Long, G., Howle, J., Haydu, L., Sharma, R., Thompson, J., Kefford, R., Hersey, P., Scolyer, R. (2012). Selective BRAF inhibitors induce marked T - cell infiltration into human metastatic melanoma. Clinical Cancer Research, 18(5), 1386-1394. [More Information]
  • Carlino, M., Fogarty, G., Long, G. (2012). Treatment of Melanoma Brain Metastases: A New Paradigm. The Cancer Journal, 18(2), 208-212. [More Information]
  • Scolyer, R., Long, G., Thompson, J. (2011). Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Molecular Oncology, 5(2), 124-136. [More Information]
  • Long, G., Menzies, A., Nagrial, A., Haydu, L., Hamilton, A., Mann, G., Hughes, T., Thompson, J., Scolyer, R., Kefford, R. (2011). Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. Journal of Clinical Oncology, 29(10), 1239-1246. [More Information]
  • Arkenau, T., Kefford, R., Long, G. (2011). Targeting BRAF for patients with melanoma. British Journal of Cancer, 104(3), 392-398. [More Information]
  • Long, G. (2007). Book review: The Molecular Biology of Cancer. Cancer Forum, 31(2), 121.
  • Long, G., Tattersall, M. (2007). Lung encasement by metastatic osteoblastic sarcoma. Medical Journal of Australia, 186(2), 100-100. [More Information]

2014

  • Shi, H., Hong, A., Kong, X., Koya, R., Song, C., Moriceau, G., Hugo, W., Yu, C., Ng, C., Chodon, T., Scolyer, R., Kefford, R., Long, G., et al (2014). A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. Cancer Discovery, 4(1), 69-79. [More Information]
  • Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R., Moriceau, G., Chodon, T., Guo, R., Johnson, D., Dahlman, K., Kefford, R., Long, G., et al (2014). Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discovery, 4(1), 80-93. [More Information]
  • Bowyer, S., Rao, A., Lyle, M., Sandhu, S., Long, G., McArthur, G., Raleigh, J., Hicks, R., Millward, M. (2014). Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Research, 24(5), 504-508. [More Information]
  • Rizos, H., Menzies, A., Pupo, G., Carlino, M., Fung, C., Hyman, J., Haydu, L., Mijatov, B., Becker, T., Boyd, S., Howle, J., Saw, R., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2014). BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Research, 20(7), 1965-1977. [More Information]
  • Kakavand, H., Crainic, O., Lum, T., O'Toole, S., Kefford, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2014). Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 46(3), 193-198. [More Information]
  • Menzies, A., Long, G. (2014). Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clinical Cancer Research, 20(8), 2035-2043. [More Information]
  • Carlino, M., Todd, J., Gowrishankar, K., Mijatov, B., Pupo, G., Fung, C., Snoyman, S., Hersey, P., Long, G., Kefford, R., Rizos, H. (2014). Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology, 8(3), 544-554. [More Information]
  • Falchook, G., Long, G., Kurzrock, R., Kim, K., Arkenau, H., Brown, M., Hamid, O., Infante, J., Millward, M., Pavlick, A., Kefford, R., et al (2014). Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF-inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research, 20(17), 4449-4458. [More Information]
  • Wilmott, J., Haydu, L., Menzies, A., Lum, T., Hyman, J., Thompson, J., Hersey, P., Kefford, R., Scolyer, R., Long, G. (2014). Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. The Journal of Immunology, 192(5), 2505-2513. [More Information]
  • Lee, C., Menzies, A., Haydu, L., Azer, M., Clements, A., Kefford, R., Long, G. (2014). Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Melanoma Research: a journal for basic, translational and clinical research in melanoma, 24(5), 468-474. [More Information]
  • Zimmer, L., Haydu, L., Menzies, A., Scolyer, R., Kefford, R., Thompson, J., Schadendorf, D., Long, G. (2014). Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. Journal of Clinical Oncology, 32(8), 816-823. [More Information]
  • Menzies, A., Haydu, L., Carlino, M., Azer, M., Carr, P., Kefford, R., Long, G. (2014). Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PLoS One, 9(1), 1-9. [More Information]
  • Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
  • Ackerman, A., Klein, O., McDermott, D., Wang, W., Ibrahim, N., Lawrence, D., Gunturi, A., Flaherty, K., Hodi, F., Kefford, R., Menzies, A., Long, G., et al (2014). Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer, 120(11), 1695-1701. [More Information]
  • Azer, M., Menzies, A., Haydu, L., Kefford, R., Long, G. (2014). Patterns of Response and Progression in Patients With BRAF-Mutant Melanoma Metastatic to the Brain Who Were Treated With Dabrafenib. Cancer, 120(4), 530-536. [More Information]
  • Parmenter, T., Kleinschmidt, M., Kinross, K., Bond, S., Li, J., Kaadige, M., Rao, A., Sheppard, K., Hugo, W., Pupo, G., Long, G., Scolyer, R., Rizos, H., et al (2014). Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discovery, 4(4), 423-433. [More Information]
  • Flaherty, K., Hennig, M., Ascierto, P., Dummer, R., Eggermont, A., Hauschild, A., Kefford, R., Kirkwood, J., Long, G., Lorigan, P., et al (2014). Surrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trials. The Lancet Oncology, 15(3), 297-304. [More Information]
  • Chien, A., Haydu, L., Biechele, T., Kulikauskas, R., Rizos, H., Kefford, R., Scolyer, R., Moon, R., Long, G. (2014). Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/Beta-Catenin Signaling. PLoS One, 9(4), 1-11. [More Information]
  • Lyle, M., Long, G. (2014). The role of systemic therapies in the management of melanoma brain metastases. Current Opinion in Oncology, 26(2), 22-229. [More Information]
  • Brown, M., Long, G. (2014). The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation. Asia-Pacific Journal of Clinical Oncology, 10(S3), 1-15. [More Information]

2013

  • Carlino, M., Saunders, C., Haydu, L., Menzies, A., Curtis, C., Lebowitz, P., Kefford, R., Long, G. (2013). 18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. European Journal of Cancer, 49(2), 395-402. [More Information]
  • Hu, W., Jin, L., Jiang, C., Long, G., Scolyer, R., Wu, Q., Zhang, X., Mei, Y., Wu, M. (2013). AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Cell Death and Disease, 4(e914), 1-11. [More Information]
  • Carlino, M., Gowrishankar, K., Saunders, C., Pupo, G., Snoyman, S., Zhang, X., Saw, R., Becker, T., Kefford, R., Long, G., Rizos, H. (2013). Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition Following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 12(7), 1332-1342. [More Information]
  • Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013). BRAF inhibitor activity in V600R metastatic melanoma. European Journal of Cancer, 49(5), 1073-1079. [More Information]
  • Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013). BRAF inhibitor activity in V600R metastatic melanoma – Response. European Journal of Cancer, 49(7), 1797-1798. [More Information]
  • Wilmott, J., Menzies, A., Haydu, L., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Diemling, A., Scolyer, R., Long, G. (2013). BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. British Journal of Cancer, 108(4), 924-931. [More Information]
  • Anforth, R., Fernandez Penas, P., Long, G. (2013). Cutaneous toxicities of RAF inhibitors. The Lancet Oncology, 14(1), e11-e18. [More Information]
  • Lyle, M., Long, G. (2013). Diagnosis and Treatment of KIT-Mutant Metastatic Melanoma. Journal of Clinical Oncology, 31(26), 3176-3181. [More Information]
  • Long, G., Wilmott, J., Haydu, L., Tembe, V., Sharma, R., Rizos, H., Thompson, J., Howle, J., Scolyer, R., Kefford, R. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment and on progression. Pigment Cell and Melanoma Research, 26(4), 499-508. [More Information]
  • Klein, O., Ribas, A., Chmielowski, B., Walker, G., Clements, A., Long, G., Kefford, R. (2013). Facial Palsy As a Side Effect of Vemurafenib Treatment in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 31(12), e215-e217. [More Information]
  • Long, G., Wilmott, J., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Deimling, A., Scolyer, R. (2013). Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. The American Journal of Surgical Pathology, 37(1), 61-65. [More Information]
  • Long, G., Margolin, K. (2013). Multidisciplinary Approach to Brain Metastasis from Melanoma: The Emerging Role of Systemic Therapies. American Society of Clinical Oncology Educational Book, 2013, 393-398. [More Information]
  • Menzies, A., Long, G. (2013). New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Therapeutic Advances in Medical Oncology, 5(5), 278-285. [More Information]
  • Menzies, A., Kefford, R., Long, G. (2013). Paradoxical oncogenesis: are all BRAF inhibitors equal? Pigment Cell and Melanoma Research, 26(5), 611-615. [More Information]
  • Trunzer, K., Pavlick, A., Schuchter, L., Gonzalez, R., McArthur, G., Hutson, T., Moschos, S., Flaherty, K., Kim, K., Weber, J., Hersey, P., Long, G., et al (2013). Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 31(14), 1767-1774. [More Information]
  • Kim, K., Kefford, R., Pavlick, A., Infante, J., Ribas, A., Sosman, J., Fecher, L., Millward, M., McArthur, G., Hwu, P., Long, G., et al (2013). Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology, 31(4), 482-489. [More Information]
  • Ascierto, P., Minor, D., Ribas, A., Lebbe, C., O'Hagan, A., Arya, N., Guckert, M., Schadendorf, D., Kefford, R., Grob, J., Long, G., et al (2013). Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 31(26), 3205-3211. [More Information]
  • Menzies, A., Long, G. (2013). Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. European Journal of Cancer, 49(15), 3229-3241. [More Information]
  • Anforth, R., Blumetti, T., Clements, A., Kefford, R., Long, G., Fernandez Penas, P. (2013). Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. British Journal of Dermatology, 169(6), 1310-1313. [More Information]
  • Nathanson, K., Martin, A., Wubbenhorst, B., Greshock, J., Letrero, R., D'Andrea, K., O'Day, S., Infante, J., Falchook, G., Arkenau, H., Kefford, R., Long, G., et al (2013). Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research, 19(17), 4868-4878. [More Information]

2012

  • Zimmer, L., Hillen, U., Livingstone, E., Lacouture, M., Busam, K., Carvajal, R., Egberts, F., Hauschild, A., Kashani-Sabet, M., Goldinger, S., Long, G., et al (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology, 30(19), 2375-2383. [More Information]
  • Murali, R., Haydu, L., Long, G., Quinn, M., Saw, R., Shannon, K., Spillane, A., Stretch, J., Kefford, R., Thompson, J., Scolyer, R. (2012). Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. Annals of Surgical Oncology, 19(6), 1782-1789. [More Information]
  • Flaherty, K., Infante, J., Daud, A., Gonzalez, R., Kefford, R., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., Long, G., et al (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England Journal of Medicine, 367(18), 1694-1703. [More Information]
  • Wilmott, J., Scolyer, R., Long, G., Hersey, P. (2012). Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. OncoImmunology, 1(6), 997-999. [More Information]
  • Anforth, R., Blumetti, T., Kefford, R., Sharma, R., Scolyer, R., Kossard, S., Long, G., Fernandez Penas, P. (2012). Cutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of Mutant BRAF in patients with Metastatic Melanoma. British Journal of Dermatology, 167(5), 1153-1160. [More Information]
  • Menzies, A., Long, G., Murali, R. (2012). Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design, Development and Therapy, 6, 391-405. [More Information]
  • Falchook, G., Long, G., Kurzrock, R., Kim, K., Arkenau, T., Brown, M., Hamid, O., Infante, J., Millward, M., Pavlick, A., Kefford, R., et al (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. The Lancet, 379(9829), 1893-1901. [More Information]
  • Long, G., Trefzer, U., Davies, M., Kefford, R., Ascierto, P., Chapman, P., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., et al (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. The Lancet Oncology, 13(11), 1087-1095. [More Information]
  • Menzies, A., Haydu, L., Visintin, L., Carlino, M., Howle, J., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2012). Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clinical Cancer Research, 18(12), 3242-3249. [More Information]
  • Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012). Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 11(12), 2704-2708. [More Information]
  • Shi, H., Moriceau, G., Kong, X., Lee, M., Lee, H., Koya, R., Ng, C., Chodon, T., Scolyer, R., Dahlman, K., Kefford, R., Long, G., et al (2012). Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications, 3(20122), 1-8. [More Information]
  • Murali, R., Brown, P., Kefford, R., Scolyer, R., Thompson, J., Atkins, M., Long, G. (2012). Number of Primary Melanomas Is an Independent Predictor of Survival in Patients With Metastatic Melanoma. Cancer, 118(18), 4519-4529. [More Information]
  • Shi, H., Moriceau, G., Kong, X., Koya, R., Nazarian, R., Pupo, G., Bacchiocchi, A., Dahlman, K., Chmielowski, B., Sosman, J., Kefford, R., Long, G., et al (2012). Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discovery, 2(5), 414-424. [More Information]
  • Wilmott, J., Long, G., Howle, J., Haydu, L., Sharma, R., Thompson, J., Kefford, R., Hersey, P., Scolyer, R. (2012). Selective BRAF inhibitors induce marked T - cell infiltration into human metastatic melanoma. Clinical Cancer Research, 18(5), 1386-1394. [More Information]
  • Carlino, M., Fogarty, G., Long, G. (2012). Treatment of Melanoma Brain Metastases: A New Paradigm. The Cancer Journal, 18(2), 208-212. [More Information]

2011

  • Scolyer, R., Long, G., Thompson, J. (2011). Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Molecular Oncology, 5(2), 124-136. [More Information]
  • Long, G., Menzies, A., Nagrial, A., Haydu, L., Hamilton, A., Mann, G., Hughes, T., Thompson, J., Scolyer, R., Kefford, R. (2011). Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. Journal of Clinical Oncology, 29(10), 1239-1246. [More Information]
  • Arkenau, T., Kefford, R., Long, G. (2011). Targeting BRAF for patients with melanoma. British Journal of Cancer, 104(3), 392-398. [More Information]

2007

  • Long, G. (2007). Book review: The Molecular Biology of Cancer. Cancer Forum, 31(2), 121.
  • Long, G., Tattersall, M. (2007). Lung encasement by metastatic osteoblastic sarcoma. Medical Journal of Australia, 186(2), 100-100. [More Information]

To update your profile click here. For support on your academic profile contact .